2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1085

Trajectories and Predictors of Physical Activity over Two Years in Rheumatoid Arthritis
Abstract Number: 1089

Trajectories of Disability over Time Among Patients with Systemic Sclerosis
Abstract Number: 1136

Transcriptional Heterogeneity of the SLC2A9 Gene Encoding the GLUT9 Urate Transporter
Abstract Number: 768

Transforming Growth Factor Beta Induces anti Angio and Vasculo-Genesis Phenotype in Dermal Fibroblasts through Secretion of Pigment Epithelium Derived Factor
Abstract Number: 1967

Transforming Growth Factor Beta Is a Major Regulator of Micro-RNA Synthesis in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1326

Transition of Care and Long-Term Outcomes of Juvenile Systemic Sclerosis during Adulthood: Results from a French Single-Center Case-Control Study
Abstract Number: 557

Translation and Cross-Cultural Adaptation of the ASAS Health Index and the environmental Item Set into 15 Languages
Abstract Number: 1731

Translocation of IGFBP-5 to the Nucleus and Its Interaction with Nucleolin Do Not Dictate Its Fibrotic Effects
Abstract Number: 1122

Transmitocondrial Cybrids: A Tool to Study the Role of mtDNA Haplogroups in OA Pathogenesis
Abstract Number: 1021

Transthyretin and Amyloid in Cartilage Aging and Osteoarthritis
Abstract Number: 2396

Treat to Target in Routine Clinical Practice
Abstract Number: 114

Treat-to-Target (T2T) and Measuring Outcomes in RA Care: a 2014 Longitudinal Survey of US Rheumatologists
Abstract Number: 2609

Treating Axial-Spa to Target: Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Anti-TNFα Agents
Abstract Number: 2483

Treatment Adjustment Strategy after Achieving Remission or Low Disease Activity in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
Abstract Number: 2026

Treatment Delays and Worse Outcomes Associated with Lower Socioeconomic Status in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].